Pelthos Therapeutics Inc. PTHS
Pelthos Therapeutics Inc. (NYSE: PTHS) is a dermatology drug developer. Its lead program, Zelsuvmi (berdazimer) topical gel, 10.3%, is in Phase 2 for molluscum contagiosum. Its next catalyst on record is Xepi: Commercial relaunch (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Xepi — Commercial relaunch (Q1 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Zelsuvmi (berdazimer) | molluscum contagiosum | small molecule | Approved |
| Xepi (ozenoxacin) cream 1% | impetigo | small molecule | Approved |
| Xeglyze (abametapir) | head lice | small molecule | Approved |
| CT2000 (CC8464 NaV1.7 inhibitor, topical) | eye pain | small molecule | Phase 2 |
| CC8464 (NaV1.7 inhibitor) | neuropathic pain (erythromelalgia, idiopathic small fiber neuropathy) | small molecule | Phase 1 |
| CT3000 (depot CC8464) | postoperative pain nerve blocks | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.